APO Research
Talk to an analyst

APO RESEARCH · REPORT

PEGylated Granulocyte-Colony Stimulating Factor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global PEGylated Granulocyte-Colony Stimulating Factor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025197 pages

Choose your research edition.

Industry ResearchPEGylated Granulocyte-Colony Stimulating Factor Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal PEGylated Granulocyte-Colony Stimulating Factor Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal PEGylated Granulocyte-Colony Stimulating Factor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PEGylated Granulocyte-Colony Stimulating Factor Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal PEGylated Granulocyte-Colony Stimulating Factor Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global PEGylated Granulocyte-Colony Stimulating Factor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for PEGylated Granulocyte-Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PEGylated Granulocyte-Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PEGylated Granulocyte-Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for PEGylated Granulocyte-Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PEGylated Granulocyte-Colony Stimulating Factor include Amgen, Coherus BioSciences, Fresenius Kabi, Kashiv BioSciences, Mylan, Pfizer, Sandoz, SL Pharm and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PEGylated Granulocyte-Colony Stimulating Factor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PEGylated Granulocyte-Colony Stimulating Factor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PEGylated Granulocyte-Colony Stimulating Factor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PEGylated Granulocyte-Colony Stimulating Factor market size, projected growth trends, production technologies, key applications, and end-use industries.

PEGylated Granulocyte-Colony Stimulating Factor Segment by Company

Amgen

Coherus BioSciences

Fresenius Kabi

Kashiv BioSciences

Mylan

Pfizer

Sandoz

SL Pharm

Jiangsu Hengrui Pharmaceuticals

Lunan Pharmaceutical

Qilu Pharmaceutical

Amoytop Biotech

CSPC Baike Biopharma

PEGylated Granulocyte-Colony Stimulating Factor Segment by Type

Telpegfilgrastim

Pegfilgrastim

Mecapegfilgrastim

Other

PEGylated Granulocyte-Colony Stimulating Factor Segment by Application

Hospital and Clinic

Pharmacy

Other

PEGylated Granulocyte-Colony Stimulating Factor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PEGylated Granulocyte-Colony Stimulating Factor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PEGylated Granulocyte-Colony Stimulating Factor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PEGylated Granulocyte-Colony Stimulating Factor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PEGylated Granulocyte-Colony Stimulating Factor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PEGylated Granulocyte-Colony Stimulating Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PEGylated Granulocyte-Colony Stimulating Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PEGylated Granulocyte-Colony Stimulating Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PEGylated Granulocyte-Colony Stimulating Factor Industry Trends Table 2. PEGylated Granulocyte-Colony Stimulating Factor Industry Drivers Table 3. PEGylated Granulocyte-Colony Stimulating Factor Industry Opportunities and Challenges Table 4. PEGylated Granulocyte-Colony Stimulating Factor Industry Restraints Table 5. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Manufacturers Table 9. Global PEGylated Granulocyte-Colony Stimulating Factor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global PEGylated Granulocyte-Colony Stimulating Factor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PEGylated Granulocyte-Colony Stimulating Factor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PEGylated Granulocyte-Colony Stimulating Factor Manufacturers, Product Type & Application Table 13. Global PEGylated Granulocyte-Colony Stimulating Factor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PEGylated Granulocyte-Colony Stimulating Factor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Telpegfilgrastim Table 17. Major Manufacturers of Pegfilgrastim Table 18. Major Manufacturers of Mecapegfilgrastim Table 19. Major Manufacturers of Other Table 20. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2021-2026) & (K Units) Table 22. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2027-2032) & (K Units) Table 23. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2021-2026) Table 24. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2027-2032) Table 25. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2021-2026) & (K Units) Table 27. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2027-2032) & (K Units) Table 28. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2021-2026) Table 29. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital and Clinic Table 31. Major Manufacturers of Pharmacy Table 32. Major Manufacturers of Other Table 33. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2021-2026) & (K Units) Table 35. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2027-2032) & (K Units) Table 36. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2021-2026) Table 37. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2027-2032) Table 38. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2021-2026) & (K Units) Table 40. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2027-2032) & (K Units) Table 41. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2021-2026) Table 42. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2027-2032) Table 43. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region (2021-2026) & (K Units) Table 45. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Region (2021-2026) Table 46. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Forecasted Market Share by Region (2027-2032) Table 48. North America PEGylated Granulocyte-Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 50. North America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 51. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 53. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 60. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2021-2026) & (US$ Million) Table 62. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2027-2032) & (US$ Million) Table 63. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Region (2021-2026) Table 64. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Region (2027-2032) Table 65. Amgen Company Information Table 66. Amgen Business Overview Table 67. Amgen PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Amgen PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 69. Amgen Recent Development Table 70. Coherus BioSciences Company Information Table 71. Coherus BioSciences Business Overview Table 72. Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 74. Coherus BioSciences Recent Development Table 75. Fresenius Kabi Company Information Table 76. Fresenius Kabi Business Overview Table 77. Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 79. Fresenius Kabi Recent Development Table 80. Kashiv BioSciences Company Information Table 81. Kashiv BioSciences Business Overview Table 82. Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 84. Kashiv BioSciences Recent Development Table 85. Mylan Company Information Table 86. Mylan Business Overview Table 87. Mylan PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Mylan PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 89. Mylan Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Pfizer PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 94. Pfizer Recent Development Table 95. Sandoz Company Information Table 96. Sandoz Business Overview Table 97. Sandoz PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Sandoz PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 99. Sandoz Recent Development Table 100. SL Pharm Company Information Table 101. SL Pharm Business Overview Table 102. SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 104. SL Pharm Recent Development Table 105. Jiangsu Hengrui Pharmaceuticals Company Information Table 106. Jiangsu Hengrui Pharmaceuticals Business Overview Table 107. Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 109. Jiangsu Hengrui Pharmaceuticals Recent Development Table 110. Lunan Pharmaceutical Company Information Table 111. Lunan Pharmaceutical Business Overview Table 112. Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 114. Lunan Pharmaceutical Recent Development Table 115. Qilu Pharmaceutical Company Information Table 116. Qilu Pharmaceutical Business Overview Table 117. Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 119. Qilu Pharmaceutical Recent Development Table 120. Amoytop Biotech Company Information Table 121. Amoytop Biotech Business Overview Table 122. Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 124. Amoytop Biotech Recent Development Table 125. CSPC Baike Biopharma Company Information Table 126. CSPC Baike Biopharma Business Overview Table 127. CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio Table 129. CSPC Baike Biopharma Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. PEGylated Granulocyte-Colony Stimulating Factor Distributors List Table 133. PEGylated Granulocyte-Colony Stimulating Factor Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. PEGylated Granulocyte-Colony Stimulating Factor Product Image Figure 2. Global PEGylated Granulocyte-Colony Stimulating Factor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PEGylated Granulocyte-Colony Stimulating Factor Market Size (2021-2032) & (US$ Million) Figure 4. Global PEGylated Granulocyte-Colony Stimulating Factor Sales (2021-2032) & (K Units) Figure 5. Global PEGylated Granulocyte-Colony Stimulating Factor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 PEGylated Granulocyte-Colony Stimulating Factor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Telpegfilgrastim Image Figure 9. Pegfilgrastim Image Figure 10. Mecapegfilgrastim Image Figure 11. Other Image Figure 12. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2021-2032) Figure 15. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2021-2032) Figure 18. Hospital and Clinic Image Figure 19. Pharmacy Image Figure 20. Other Image Figure 21. Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2021-2032) Figure 24. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2021-2032) Figure 27. North America PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 29. U.S. PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 34. Germany PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 41. China PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Country (2021-2032) Figure 49. Brazil PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile PEGylated Granulocyte-Colony Stimulating Factor Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America PEGylated Granulocyte-Colony Stimulating Factor Revenue (2021-2032) & (US$ Million) Figure 60. North America PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue (2021-2032) & (US$ Million) Figure 62. Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. PEGylated Granulocyte-Colony Stimulating Factor Value Chain Figure 68. Manufacturing Cost Structure Figure 69. PEGylated Granulocyte-Colony Stimulating Factor Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Telpegfilgrastim
  • Pegfilgrastim
  • Mecapegfilgrastim
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Amgen
  • Coherus BioSciences
  • Fresenius Kabi
  • Kashiv BioSciences
  • Mylan
  • Pfizer
  • Sandoz
  • SL Pharm
  • Jiangsu Hengrui Pharmaceuticals
  • Lunan Pharmaceutical
  • Qilu Pharmaceutical
  • Amoytop Biotech
  • CSPC Baike Biopharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PEGylated Granulocyte-Colony Stimulating Factor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PEGylated Granulocyte-Colony Stimulating Factor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PEGylated Granulocyte-Colony Stimulating Factor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PEGylated Granulocyte-Colony Stimulating Factor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PEGylated Granulocyte-Colony Stimulating Factor Market Dynamics
  1. 2.1 PEGylated Granulocyte-Colony Stimulating Factor Industry Trends
  2. 2.2 PEGylated Granulocyte-Colony Stimulating Factor Industry Drivers
  3. 2.3 PEGylated Granulocyte-Colony Stimulating Factor Industry Opportunities and Challenges
  4. 2.4 PEGylated Granulocyte-Colony Stimulating Factor Industry Restraints
3 PEGylated Granulocyte-Colony Stimulating Factor Market by Manufacturers
  1. 3.1 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Manufacturers (2021-2026)
  3. 3.3 Global PEGylated Granulocyte-Colony Stimulating Factor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PEGylated Granulocyte-Colony Stimulating Factor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PEGylated Granulocyte-Colony Stimulating Factor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PEGylated Granulocyte-Colony Stimulating Factor Manufacturers, Product Type & Application
  7. 3.7 Global PEGylated Granulocyte-Colony Stimulating Factor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PEGylated Granulocyte-Colony Stimulating Factor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PEGylated Granulocyte-Colony Stimulating Factor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PEGylated Granulocyte-Colony Stimulating Factor Tier 1, Tier 2, and Tier 3
4 PEGylated Granulocyte-Colony Stimulating Factor Market by Type
  1. 4.1 PEGylated Granulocyte-Colony Stimulating Factor Type Introduction
  2. 4.1.1 Telpegfilgrastim
  3. 4.1.2 Pegfilgrastim
  4. 4.1.3 Mecapegfilgrastim
  5. 4.1.4 Other
  6. 4.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type
  7. 4.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Type (2021-2032)
  9. 4.2.3 Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Type (2021-2032)
  10. 4.3 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type
  11. 4.3.1 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Type (2021-2032)
  13. 4.3.3 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Type (2021-2032)
5 PEGylated Granulocyte-Colony Stimulating Factor Market by Application
  1. 5.1 PEGylated Granulocyte-Colony Stimulating Factor Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application
  6. 5.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Application (2021-2032)
  8. 5.2.3 Global PEGylated Granulocyte-Colony Stimulating Factor Sales Market Share by Application (2021-2032)
  9. 5.3 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application
  10. 5.3.1 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Application (2021-2032)
  12. 5.3.3 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Application (2021-2032)
6 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region
  1. 6.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region (2021-2032)
  3. 6.2.1 Global PEGylated Granulocyte-Colony Stimulating Factor Sales by Region (2021-2026)
  4. 6.2.2 Global PEGylated Granulocyte-Colony Stimulating Factor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PEGylated Granulocyte-Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PEGylated Granulocyte-Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region
  1. 7.1 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region
  2. 7.1.1 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2021-2026)
  4. 7.1.3 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue by Region (2027-2032)
  5. 7.1.4 Global PEGylated Granulocyte-Colony Stimulating Factor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PEGylated Granulocyte-Colony Stimulating Factor Revenue (2021-2032)
  8. 7.2.2 North America PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue (2021-2032)
  11. 7.3.2 Europe PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PEGylated Granulocyte-Colony Stimulating Factor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Coherus BioSciences
  8. 8.2.1 Coherus BioSciences Company Information
  9. 8.2.2 Coherus BioSciences Business Overview
  10. 8.2.3 Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Coherus BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  12. 8.2.5 Coherus BioSciences Recent Developments
  13. 8.3 Fresenius Kabi
  14. 8.3.1 Fresenius Kabi Company Information
  15. 8.3.2 Fresenius Kabi Business Overview
  16. 8.3.3 Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Fresenius Kabi PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  18. 8.3.5 Fresenius Kabi Recent Developments
  19. 8.4 Kashiv BioSciences
  20. 8.4.1 Kashiv BioSciences Company Information
  21. 8.4.2 Kashiv BioSciences Business Overview
  22. 8.4.3 Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Kashiv BioSciences PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  24. 8.4.5 Kashiv BioSciences Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Sandoz
  38. 8.7.1 Sandoz Company Information
  39. 8.7.2 Sandoz Business Overview
  40. 8.7.3 Sandoz PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sandoz PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  42. 8.7.5 Sandoz Recent Developments
  43. 8.8 SL Pharm
  44. 8.8.1 SL Pharm Company Information
  45. 8.8.2 SL Pharm Business Overview
  46. 8.8.3 SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 SL Pharm PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  48. 8.8.5 SL Pharm Recent Developments
  49. 8.9 Jiangsu Hengrui Pharmaceuticals
  50. 8.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 8.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 8.9.3 Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Hengrui Pharmaceuticals PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  54. 8.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 8.10 Lunan Pharmaceutical
  56. 8.10.1 Lunan Pharmaceutical Company Information
  57. 8.10.2 Lunan Pharmaceutical Business Overview
  58. 8.10.3 Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lunan Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  60. 8.10.5 Lunan Pharmaceutical Recent Developments
  61. 8.11 Qilu Pharmaceutical
  62. 8.11.1 Qilu Pharmaceutical Company Information
  63. 8.11.2 Qilu Pharmaceutical Business Overview
  64. 8.11.3 Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Qilu Pharmaceutical PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  66. 8.11.5 Qilu Pharmaceutical Recent Developments
  67. 8.12 Amoytop Biotech
  68. 8.12.1 Amoytop Biotech Company Information
  69. 8.12.2 Amoytop Biotech Business Overview
  70. 8.12.3 Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amoytop Biotech PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  72. 8.12.5 Amoytop Biotech Recent Developments
  73. 8.13 CSPC Baike Biopharma
  74. 8.13.1 CSPC Baike Biopharma Company Information
  75. 8.13.2 CSPC Baike Biopharma Business Overview
  76. 8.13.3 CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CSPC Baike Biopharma PEGylated Granulocyte-Colony Stimulating Factor Product Portfolio
  78. 8.13.5 CSPC Baike Biopharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PEGylated Granulocyte-Colony Stimulating Factor Value Chain Analysis
  2. 9.1.1 PEGylated Granulocyte-Colony Stimulating Factor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PEGylated Granulocyte-Colony Stimulating Factor Production Mode & Process
  6. 9.2 PEGylated Granulocyte-Colony Stimulating Factor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PEGylated Granulocyte-Colony Stimulating Factor Distributors
  9. 9.2.3 PEGylated Granulocyte-Colony Stimulating Factor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst